Spring Bank’s revelation of liver toxicity in chronic HBV patients treated with inarigivir soproxil in a Phase IIb trial sent the company’s shares down 67% Thursday; however, the readout doesn’t necessarily mean that immuno-oncology therapies...

Abalos launched Tuesday with a €12 million ($13.2 million) series A round to advance its arenavirus-based cancer therapies, which offer an alternative to oncolytic viruses, and rely on prolonged immune responses to clear tumors. Boehringer...

STipe, the first company out of Novo’s BioInnovation Initiative, raised €20 million ($21.9 million) in a series A round to develop technology designed to improve the therapeutic window of STING modulators in the clinic. Novo...

Takeouts of portfolio companies Rigontec and Symetis, coupled with a focus on biotechs in Germany, Austria and Switzerland, helped Wellington Partners raise its largest fund to date. Wellington announced Wednesday the close of Wellington Partners...

Forbion Capital Partners raised €270 million ($317.8 million) toward Forbion IV, surpassing its target of €250 million. The firm said the fund will have a "sharper focus" on biotech investments than Forbion Capital Fund III...

With global investors’ interest in European start-ups rising, Forbion Capital Partners plans to emphasize building new companies from scratch as it invests its fourth fund. The firm hopes that by building strong relationships early in...

Forbion Capital Partners raised €270 million ($317.8 million) toward Forbion IV, surpassing its target of €250 million ($294.2 million). The firm said the fund will have a "sharper focus" on biotech investments than Forbion Capital...

Zhijian “James” Chen’s discovery of the DNA sensor cGAS revealed the missing link between cytosolic DNA and innate immune activation, paving the way for immunotherapies targeting the cGAS-STING pathway. The lowest-hanging fruit has been in...

Boehringer Ingelheim GmbH (Ingelheim, Germany) said on Jan. 3 it added €150 million ($178.1 million) to its Boehringer Ingelheim Venture Fund, boosting its total to €250 million ($296.9 million), and is expanding the fund's investment...

Boehringer Ingelheim GmbH (Ingelheim, Germany) added €150 million ($178.1 million) to its Boehringer Ingelheim Venture Fund, boosting its total to €250 million ($296.9 million), and is expanding the fund's investment focus to include regenerative medicine,...